# Aktis Oncology, Inc. (AKTS)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/aktis-oncology-inc/ JSON: https://steadybase.io/company/aktis-oncology-inc.json Checked Nov 10, 2026. Latest filing read: Aug 13, 2026.

## Company

- Legal name: Aktis Oncology, Inc.
- Ticker: AKTS (Nasdaq)
- SEC CIK: 0002035832
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: Boston, MA
- Fiscal year ends: December 31
- SEC filer category: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Website: aktisoncology.com
- LinkedIn: https://www.linkedin.com/company/aktis-oncology
- Next earnings date: Nov 12, 2026

## Key facts

- Employees: 79 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/2035832/000119312526131748/aktis_12.31.25_10k.htm

## Business

We are a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The field of targeted radiopharmaceuticals is currently led by two marketed products that illustrated transformative survival outcomes and quality of life benefits can be conferred by delivering radioisotopes to solid tumors.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/2035832/000119312526131748/aktis_12.31.25_10k.htm

## Officers and directors

- Matthew Roden, PhD, President and Chief Executive Officer. Source: 10-K filed Mar 30, 2026, https://www.sec.gov/Archives/edgar/data/2035832/000119312526131748/aktis_12.31.25_10k.htm
- Matthew Roden, President and CEO. LinkedIn: https://linkedin.com/in/matthew-roden-26499a43. Source: Form 3 filed Jan 8, 2026, https://www.sec.gov/Archives/edgar/data/2035832/000119312526008065/0001193125-26-008065-index.htm
- Kyle D. Kuvalanka, Chief Financial Officer. LinkedIn: https://linkedin.com/in/kyle-kuvalanka-960a592b. Source: 10-K filed Mar 30, 2026, https://www.sec.gov/Archives/edgar/data/2035832/000119312526131748/aktis_12.31.25_10k.htm
- Shulamit Ron-Bigger, Chief Operating Officer. LinkedIn: https://linkedin.com/in/shulamit-ron-bigger-2047172b. Source: Form 4 filed Jul 10, 2026, https://www.sec.gov/Archives/edgar/data/2035832/000119312526300163/0001193125-26-300163-index.htm
- Shulamit Ron-Bigger, PhD, Chief Operating Officer. Source: 10-K filed Mar 30, 2026, https://www.sec.gov/Archives/edgar/data/2035832/000119312526131748/aktis_12.31.25_10k.htm
- Akos Czibere, Chief Medical Officer. Source: Form 4 filed Sep 24, 2026, https://www.sec.gov/Archives/edgar/data/2035832/000119312526401014/0001193125-26-401014-index.htm
- Akos Czibere, MD, PhD, Chief Medical Officer. Source: 10-K filed Mar 30, 2026, https://www.sec.gov/Archives/edgar/data/2035832/000119312526131748/aktis_12.31.25_10k.htm
- Paul L. Feldman, PhD, Chief Scientific Officer. Source: 10-K filed Mar 30, 2026, https://www.sec.gov/Archives/edgar/data/2035832/000119312526131748/aktis_12.31.25_10k.htm
- Tyler Benedum, PhD, Chief Technical Officer. Source: 10-K filed Mar 30, 2026, https://www.sec.gov/Archives/edgar/data/2035832/000119312526131748/aktis_12.31.25_10k.htm
- Paul L. Feldman, Chief Scientific Officer. LinkedIn: https://linkedin.com/in/paul-feldman-6022a2b7. Source: Form 3 filed Jan 8, 2026, https://www.sec.gov/Archives/edgar/data/2035832/000119312526008060/0001193125-26-008060-index.htm
- Helen S. Kim, MBA, Director. Source: 10-K filed Mar 30, 2026, https://www.sec.gov/Archives/edgar/data/2035832/000119312526131748/aktis_12.31.25_10k.htm
- Ken Herrmann, MD, Director. Source: 10-K filed Mar 30, 2026, https://www.sec.gov/Archives/edgar/data/2035832/000119312526131748/aktis_12.31.25_10k.htm

## Recent 8-K events

- Aug 13, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2035832/000119312526349133/ck0002035832-20260813.htm
- May 11, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2035832/000119312526216716/ck0002035832-20260511.htm
- Apr 16, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2035832/000119312526158944/d110479d8k.htm
- Mar 30, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2035832/000119312526132524/ck0002035832-20260330.htm
- Jan 12, 2026: Item 5.03, Amendments to articles or bylaws; change in fiscal year; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2035832/000119312526010354/d932945d8k.htm

## Insider trades (Form 4)

- Sep 23, 2026: Akos Czibere (Chief Medical Officer) sold 12,500 shares, about $258,592. Source: https://www.sec.gov/Archives/edgar/data/2035832/000119312526401014/0001193125-26-401014-index.htm
- Jul 20, 2026: Ken Herrmann (Director) sold 4,856 shares, about $119,263. Source: https://www.sec.gov/Archives/edgar/data/2035832/000119312526310991/0001193125-26-310991-index.htm
- Jul 17, 2026: Ken Herrmann (Director) sold 3,065 shares, about $77,269. Source: https://www.sec.gov/Archives/edgar/data/2035832/000119312526309115/0001193125-26-309115-index.htm
- Jul 8, 2026: Shulamit Ron-Bigger (Chief Operating Officer) sold 50,000 shares, about $1.4M. Source: https://www.sec.gov/Archives/edgar/data/2035832/000119312526300163/0001193125-26-300163-index.htm
- Jul 8, 2026: Akos Czibere (Chief Medical Officer) sold 50,000 shares, about $1.4M. Source: https://www.sec.gov/Archives/edgar/data/2035832/000119312526300162/0001193125-26-300162-index.htm
- Jan 12, 2026: Todd Foley (Director) bought 232,870 shares, about $4.2M. Source: https://www.sec.gov/Archives/edgar/data/2035832/000147393026000005/0001473930-26-000005-index.htm
- Jan 12, 2026: Helen Susan Kim (Director) bought 835,000 shares, about $15.0M. Source: https://www.sec.gov/Archives/edgar/data/2035832/000119312526010566/0001193125-26-010566-index.htm
- Jan 12, 2026: Oleg Nodelman (Director) bought 2,222,222 shares, about $40.0M. Source: https://www.sec.gov/Archives/edgar/data/2035832/000093583626000031/0000935836-26-000031-index.htm
- Jan 12, 2026: Capital LLC EcoR1 (Director) bought 2,222,222 shares, about $40.0M. Source: https://www.sec.gov/Archives/edgar/data/2035832/000093583626000031/0000935836-26-000031-index.htm

## Latest filings

- 8-K filed Aug 13, 2026: https://www.sec.gov/Archives/edgar/data/2035832/000119312526349133/ck0002035832-20260813.htm
- 10-K filed Mar 30, 2026: https://www.sec.gov/Archives/edgar/data/2035832/000119312526131748/aktis_12.31.25_10k.htm
- 10-Q filed Aug 13, 2026: https://www.sec.gov/Archives/edgar/data/2035832/000119312526349144/ck0002035832-20260630.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/